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interested in prodromal states and psychological risk factors that may predict the outbreak of psychotic symptoms,
but are also amenable to change. In recent years, depressive symptomshave beenproposed as precursors of psycho-
sis and some interventional studies indicate that the amelioration of depressive symptoms and depression-related
thinking styles (e.g., worrying) improves positive symptoms, thereby “killing two birds with one stone”. Yet, in a
prior study, we were unable to find a strong specific predictive role of depression on paranoia over three years,
which may have been due to the use of a nonclinical sample with minimal/mild symptom fluctuations. To address
this further, in the present studywe adopted a similarmethodological approach but assessed a large patient sample
with a schizophrenia spectrum disorder at three assessment points; baseline (N = 250), 6 weeks later (n= 207,
82.8% retention) and 6 months after baseline (n= 185, 74% retention). Using cross-lagged modeling, we assessed
paranoia with the respective items from the Positive and Negative Syndrome Scale (PANSS) and the Psychosis Rat-
ing Scales (PSYRATS) delusions subscale. Depressionwasmeasured using the Patient HealthQuestionnaire-9 (PHQ-
9) and the CalgaryDepression Scale for Schizophrenia (CDSS).We could identify a significant pathway fromdepres-
sion to paranoia from baseline to post (negative association) but not from post to follow-up. Paranoia significantly
predicted depressive symptoms for both intervals. Ourfindings do not refute claims that depressionmay precede or




Positive and Negative Syndrome Scale (PANSS)
Psychosis Rating Scales (PSYRATS)1. Introduction
1.1. Schizophrenia and affective disorders - now and then
Since the days of Emil Kraepelin, schizophrenia (then called dementia
praecox) has been distinguished from affective illness; both disorders
were regarded as etiologically separable diseases (Moritz et al., 2019).
This view has diminished over the years and it is now acknowledged
that depression and schizophrenia can coexist as in schizoaffective disor-
der or post-psychotic depression. Influential researchers such as Crow
(1995) even presume an “Einheitspsychose”, that is, a shared vulnerabil-
ity of the two. According to this view,mania, depression andpsychosis are
differentmanifestations of similar vulnerability factors and indeedgenetic
overlap seems to be high (e.g., Cardno and Owen, 2014; Wray et al.,
2018). Approximately 50% of schizophrenia patients suffer from depres-
sive symptoms that require treatment (Buckley et al., 2009) and evenz).more display subclinical symptoms. The prevalence of these symptoms
seems to differ across the different phases of the disorder. Upthegrove
(2009) has gathered data showing that the prevalence of depression is
up to 83% in high-risk states, up to 5% in acute cases, and up to 54%
after a psychotic episode. Not surprisingly, depression is among the symp-
toms patients prefer to be treated first, even before positive symptoms,
the classical target of psychiatric treatment (Byrne et al., 2010; Kuhnigk
et al., 2012; Moritz et al., 2017a).
1.2. Depression as a precursor or even risk factor for paranoia
In the last decades, researchers have begun to explore the dynamics
between psychosis and core depressive symptoms (e.g., low mood, lack
of drive) or depressive thinking styles (e.g, worry). Evidence for an asso-
ciation between depressive symptoms and psychosis has evolved from
different branches of research. The ABC study by Häfner and colleagues
(Häfner et al., 2013) was among the first to suggest that depression
may be part of the (unspecific) clinical high risk state of psychosis. This
study used retrospective assessment, which has severe methodological
limitations (e.g., memory biases such as the telescoping effect, attribu-
tional biases/search for meaning, locus of control, etc.). To address these
shortcomings, current research increasingly adopts the experience sam-
plingmethod (ESM;Myin-Germeys et al., 2018), which allows the detec-
tion of prospective associations between precursors and psychotic
symptoms in the daily life of participants. ESM studies suggest that core
features of depression precede psychotic symptoms, particularly para-
noia. Among such precursors are low self-esteem, experiential avoidance
(Udachina et al., 2014), and worry (Hartley et al., 2014). In addition, psy-
chotic symptoms are preceded by “negative affect”, a term subsuming
feelings of sadness and anxiety but also loneliness or tension (Ben-Zeev
et al., 2011; Kramer et al., 2014; Lüdtke et al., 2017; So et al., 2018).
Based on these and other findings, an influential model advocated by
British researchers (Freeman, 2016; Freeman and Garety, 2014; Garety
and Freeman, 2013) ascribes depression and depression-related symp-
toms a pivotal role for the pathogenesis of paranoia. They propose that
emotional biases (i.e., negative beliefs about the self, worrying and inter-
personal sensitivity) and sleep problems along with cognitive biases (in-
flexibility, jumping to conclusions) lead to paranoia. Support for this
model stems from evidence that interventions targeted at these alleged
risk factors (e.g., mindfulness, CBT for insomnia) decrease paranoid
symptoms (Bullock et al., 2016; Collip et al., 2013; Ellett et al., 2008;
Foster et al., 2010; Freeman et al., 2014; Freeman et al., 2015, 2016;
Hepworth et al., 2011; Myers et al., 2011; Visceglia and Lewis, 2011).
Yet, some of these studies are compromised by small sample size. More-
over, target populations (nonclinical individuals andpatientswith schizo-
phrenia) and outcomes varied across studies. In addition, not all studies
accord to predictions made by the model. For example, in a longitudinal
study with adolescents/young adults, Sullivan et al. (2014) found that
psychotic experiences but not depressive symptoms in 12-year-old chil-
dren predicted psychotic experiences when they turned 18. In two
other randomized controlled intervention trials that targeted depression,
depressive but not positive symptoms were significantly reduced in
schizophrenia patients (Moritz et al., 2015a, 2015b, 2016), which could,
however, be due to the lack of a follow-up assessment. A brief
compassion-focused imagery treatment improved emotional well-being
in paranoid patients but did not impact paranoia (Ascone et al., 2017).
Some inconsistencies in findings likely mirror unresolvedmethodo-
logical problems. For example, standard regression procedures seem to
overestimate the longitudinal association between depression and
paranoia, even after adjusting for concurrent psychopathology because
of thehigh cross-sectional association between symptoms of depression
and paranoia measured at the same time-point, and the rather strong
stability of the syndromes in terms of high auto-correlations across
time. In this regard, cross-lagged models are deemed advantageous
(for an overview, see Selig and Little, 2012).
In a recent study (Moritz et al., 2017b), we further explored the rela-
tionships between paranoia and depression. While we found that the af-
fective symptoms emphasized in Freeman and Garety's model
(e.g., worrying) predicted psychosis after six months and two years, the
predictive strength of those depressive symptoms, which are not part of
in their model, was comparable. No significant relationship emerged be-
tween depression and paranoia at baseline and six months. At trend,
worry/rumination predicted paranoia from baseline to six months,
which achieved significance from six months to two years. Avoidant be-
havior and sleep problems did not predict subsequent paranoia at any
time point; rather, paranoia at baseline predicted poor sleep as well as
overall depression severity at sixmonths. However, as this study included
neither a clinical nor a high-risk sample (in fact many participants were
much older than the typical age at first episode), this finding does not re-
fute the aforementioned causal model.
1.3. Psychosis, particularly paranoia, as a precursor or even risk factor for
depression
While the majority of contemporary research is targeted at the pos-
sible predictive role depression plays for paranoia, the opposite rela-
tionship, for which the term “post-psychotic depression” has beencoined, also deserves consideration. Early research has implicated side
effects of antipsychotic treatment as a cause for subsequent depression
(Floru et al., 1975), while more recent studies have shifted the perspec-
tive to psychological factors. Post-psychotic depression occurs once the
“curtain of paranoia” is lifted; that is, once an individual realizes the con-
sequences of his or her actions, which often range from shattered social
relationships and isolation (Sandhu et al., 2013) to severe judicial prob-
lems in case of violent acts against people or objects. Birchwood,
Upthegrove and others view the psychotic episode as a traumatic
event that elicits feelings of loss (Sandhu et al., 2013), humiliation,
shame (Turner et al., 2013; Upthegrove, 2009; Upthegrove et al.,
2014) and perceived low social rank (Birchwood et al., 2005). These fac-
tors together with enhanced illness insight (Iqbal et al., 2000) are risk
factors for depression and even suicide (Jackson et al., 2011;
Schwartz-Stav et al., 2006).
1.4. The present study
To address some of the aforementioned limitations of prior research,
particularly small sample sizes, recruitment of non-clinical samples and
methodological problems associated with simple regression, in the
present study we investigated a large patient sample currently being
treated for a schizophrenia spectrumdisorder (either in- or outpatients)
at three different points in time (baseline, six weeks, six months post-
assessment). Analyses were conducted using cross-lagged models.
Paranoia was assessed with the respective items of the Positive and
Negative Syndrome Scale (PANSS) as well as the delusions subscale of
the Psychotic SymptomRating Scales (PSYRATS). Depressive symptoms
were assessed with the PHQ-9 as well as the Calgary Depression Scale
for Schizophrenia (CDSS).Whilewe expected a direct path fromdepres-
sion to paranoia, we were also prepared to find the opposite effect as
paranoia likely exerts a detrimental effect on well-being.
2. Methods
2.1. Sample
The samplewas comprised of patientswith a primary diagnosis of psy-
chosis (including schizophrenia and schizoaffective disorder but not
schizotypal personality disorder) as diagnosed by an experienced clinician
based on the Mini International Neuropsychiatric Interview (M.I.N.I.) and
other diagnostic information. Patients were between 18 and 65 years old
and able to provide written informed consent. No symptom severity cut-
off was applied. Patients were recruited from the in- and outpatient psy-
chosis units of the University Medical Center Hamburg-Eppendorf, as
well as throughword ofmouth, practitioners in the community andadver-
tisements. The studywas approved by the ethics board of theGermanPsy-
chological Association (SM 102012_amd_032015) and registered in the
German Clinical Trials Register (DRKS 00008001).
The following additional exclusion criteria were applied: acute
suicidality/concrete suicidal plans; presence of severe neurological dis-
eases (e.g., dementia, epilepsy); alcohol or drug dependence (alcohol
or drug abuse were tolerated); IQ b 70 points as measured with the
“Worthschatztest” (Schmidt and Metzler, 1992); score ≥ 5 for uncoop-
erative behavior (item G8) and hostility (item P7) as measured by the
Positive and Negative Syndrome Scale (PANSS); participation in MCT
+ in the past 12 months.
Most patients were chronic and had been admitted to a psychiatric
hospital several times (M = 5.82). For only 15.6% of the sample the
present stay was their first (see Table 1).
2.2. Measures
2.2.1. Mini International Neuropsychiatric Interview (M.I.N.I.) 5.0.0
TheM.I.N.I. Version 5.0.0 (Sheehan et al., 1998) is a structured inter-
view for the diagnosis of axis I disorders according to DSM-IV. The
Table 1
Demographic, treatment-related and psychopathological characteristics of the sample at
baseline (N = 250).
Variables Mean (standard deviation)
or frequency
Demographic variables
Age in years 39.28 (11.08)
Gender (male, female) 144/106 (57.6%, 42.4%)
Education level (at least 12th grade vs. b12 years) 126/124 (50.5%, 49.5%)
Formal education in years 11.09 (1.92)
Post-secondary education in years 3.77 (3.00)
Treatment-related variables
Admissions (including present one); % first
admission
5.82 (5.79); 15.6% first
admission (n = 39)











PANSS delusion score 10.18 (4.30)
PSYRATS delusions score 9.94 (7.50)
PHQ-9 10.91 (5.71)
CDSS 5.10 (4.28)
PANSS total score 60.16 (16.29)
Notes. CDSS=CalgaryDepression Scale for Schizophrenia, PANSS=Positive andNegative
Syndrome Scale (PANSS), PHQ-9 = Patient Health Questionnaire- 9 (depression),
PSYRATS = Psychosis Rating Scales, Delusions Subscale.sections for depression, dysthymia, suicidality, mania, substance use
disorders, psychotic disorders, panic disorder, agoraphobia, social pho-
bia, obsessive-compulsive disorder, post-traumatic stress disorder, gen-
eralized anxiety disorder and eating disorders were administered. The
original scale was supplemented by self-devised items to ensure a diag-
nosis according to DSM-5.
2.2.2. Positive and Negative Syndrome Scale (PANSS)
The PANSS is a semi-structured interview that includes a total of 30
items capturing many symptoms typical of schizophrenia as well as
more general psychopathology over the last seven days (Kay et al.,
1987). These items are scored on a scale ranging from 1 to 7, with 7
being the most severe rating. In addition, six items from the Positive
and Negative and Disorganized Symptoms Scale (PANADSS) (Moritz
et al., 2001) were added to this instrument, which specify PANSS
items P2 (formal mental disorder), N1 (affect flattening), and P3 (hallu-
cinations). For item P2, the PANADSS distinguishes between association
loosening and speech blockage/mutism, for itemN1, it distinguishes be-
tween flat and inadequate affect, and for item P3, it differentiates be-
tween acoustic and other hallucinations. For this study, the items P1
(Delusions), P5 (Delusions of Grandeur), P6 (Delusions of Mistrust/Per-
secution) and G9 (Unusual Thought Contents) were aggregated to ob-
tain a paranoia score (range 4–28 points).
2.2.3. Psychosis Rating Scales (PSYRATS)
The PSYRATS is an expert rating sale consisting of two subscales,
which inquire about auditory hallucinations and delusions over the
course of the last seven days (Haddock et al., 1999). Response options
range from 0 to 4 resulting in a possible total sum value between 0
and 24 points. Hallucinations and delusions are captured in a more dif-
ferentiated way than in the PANSS (e.g., loudness of voices, degree of
conviction for false beliefs).
2.2.4. Calgary Depression Scale for Schizophrenia (CDSS)
The CDSS is a semi-structured expert rating scale which contains
nine items andwas specifically developed tomeasure depressive symp-
toms in schizophrenia beyond positive and negative symptoms
(Addington et al., 1992). Construct validity has been confirmed bysubstantial correlations with other depression scales, such as the Ham-
ilton Depression Rating Scale or the Beck Depression Inventory. The in-
strument has an excellent interrater reliability for the German version
used with a κ coefficient of 0.97 (Müller et al., 1999). All nine items
are rated on a Likert scale from 0 to 3 and refer to the last seven days,
where item 9 reflects the interviewer's observation. The total score
ranges from 0 to 27 points.
2.2.5. The Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 (Gilbody et al., 2007; Kroenke et al., 2001) was used to
assess subjective depressive symptoms. Its items match the nine diag-
nostic criteria for depression according to DSM-IV (scoring: not at all
(=0), several days (=1), more than half the days (=2), nearly every
day (=3)). The scale was derived from the Primary Care Evaluation of
Mental Disorders (PRIMEMD) and its psychometric properties are
good (Gilbody et al., 2007).
2.3. Statistical analyses
All analyses were performed with Mplus version 8.0 (Muthén and
Muthén, 2015). To test the measurement models for depression and
paranoia at all assessment-points, we first computed confirmatory fac-
tor analyses (CFA). The latent variable “paranoia”was formed by two in-
dicators: the summary score for paranoia items from the PANSS (items
P1, P5, P6, G9) and PSYRATS (Haddock et al., 1999). The latent variable
“depression” was also formed by two indicators: the total score of the
CDSS (Addington et al., 1992) and the PHQ-9 (Gilbody et al., 2007;
Kroenke et al., 2001). By using aggregated scores, we intended to in-
crease the reliability of parameter estimates (Little et al., 2013). The lon-
gitudinal measurement invariance of the measurement models was
investigated using a single group approach by first running uncon-
strained models with freely estimated parameter estimates. We then
constrained factor loadings in tandem to be equal over time. The uncon-
strained and the constrained models were compared in terms of
changes in Goodness of Fit and modification indices (Brown, 2015;
Little, 2013). In Appendix A, we also report item-wise predictors. How-
ever, interpretation of these models is constrained by low reliability.
We usedmultiple imputations for all variables included in the cross-
lagged panel models while assuming random missingness. We
employed the Bayes estimator (Asparouhov and Muthén, 2010),
which employs Markov chain Monte Carlo (MCMC) algorithms, to im-
putemissingdata (100 imputeddatasetswere generated; results are re-
ported based on pooled analyses of these datasets). Sensitivity analyses
revealed similar result patterns for multiple imputations or complete
cases. Model fit was determined by the following commonly used indi-
ces: Comparative Fit Index (CFI), RootMean Square Error of Approxima-
tion (RMSEA) and Tucker Lewis Index (TLI).
Reciprocal effects among depressive and paranoid symptom across
time were tested by calculating cross-lagged panel models, which pro-
vide estimates for the stability of constructs by regressing later mea-
sures onto earlier measures of the same construct to produce stability
coefficients. Earlier measures of one construct (e.g., depression) are
used to predict the later measure of the other construct
(e.g., paranoia), which is called a cross-lagged association (Curran,
2000). Thereby, cross-lagged panel models allow for simultaneous esti-
mation of reciprocal influences of depression and paranoia over and
above the prior level of these constructs. We controlled our cross-
lagged panel models for age, gender and education. Furthermore,
indicator-specific effects were estimated to model the shared method
variance of indicators for both depression and paranoia over time in-
stead of calculating correlated error variables to avoid an underestima-
tion of reliability of indicators (Geiser and Lockhart, 2012). As model fit
indices are limited in Mplus using Bayes estimator, we reported model
fit based on Maximum Likelihood estimation. Effect sizes were
expressed as correlation coefficients and pre-post effect sizes ([Mpost
Table 2
Means, standard deviations and changes over time in paranoia and depression.
T0 T1 T2 Wald-test T0/T1a p T0-T1
ES
Wald-test T1/T2a p T0-T2
ES
Mean (SD) Mean (SD) Mean (SD)
Paranoia (PANSS) 10.18 (4.29) 8.09 (3.94) 7.75 (4.08) 32.08 b0.001 0.49 36.94 b0.001 0.57
Paranoia (Psyrats) 9.98 (7.50) 6.90 (7.24) 6.79 (7.34) 23.75 b0.001 0.41 22.53 b0.001 0.43
Depression (PHQ) 11.11 (7.78) 9.13 (5.51) 9.27 (5.52) 15.24 b0.001 0.25 9.57 b0.01 0.24
PHQ 1: Anhedonia 1.21 (0.97) 1.05 (0.86) 1.22 (0.90) 3.31 0.069 0.16 0.02 0.886 −0.01
PHQ 2: Depressed mood 1.34 (0.93) 1.11 (0.89) 1.11 (0.87) 7.54 b0.01 0.25 5.76 0.016 0.25
PHQ 3: Trouble sleeping 1.57 (1.04) 1.30 (1.03) 1.44 (1.06) 8.59 b0.01 0.26 1.46 0.227 0.13
PHQ 4: Feeling tired 1.52 (1.01) 1.36 (0.95) 1.38 (0.95) 4.20 b0.05 0.16 1.96 0.161 0.14
PHQ 5: Change in appetite 1.21 (1.04) 1.02 (0.98) 0.98 (0.98) 4.10 b0.05 0.18 4.19 b0.05 0.22
PHQ 6: Guilt, worthlessness 1.26 (1.06) 0.93 (0.91) 0.96 (0.97) 14.39 b0.001 0.31 8.13 b0.01 0.28
PHQ 7: Concentrating 1.43 (1.00) 1.12 (0.93) 1.02 (0.91) 12.67 b0.001 0.31 20.14 b0.001 0.41
PHQ 8: Slowed down/restless 0.96 (0.98) 0.70 (0.88) 0.67 (0.85) 10.84 b0.01 0.27 9.73 b0.01 0.30
PHQ 9: Suicidal thoughts 0.58 (0.84) 0.51 (0.82) 0.43 (0.75) 0.66 0.415 0.08 2.15 0.142 0.18
Depression (CDSS) 5.09 (4.27) 4.39 (4.04) 4.29 (4.20) 5.26 b0.05 0.16 4.55 b0.05 0.19
CDSS 1: Depression 0.96 (0.97) 0.91 (0.93) 0.79 (0.87) 0.58 0.448 0.05 4.59 b0.05 0.18
CDSS 2: Hopelessness 0.72 (0.83) 0.62 (0.76) 0.63 (0.79) 2.17 0.141 0.12 1.86 0.173 0.11
CDSS 3: Self-depreciation 0.78 (0.95) 0.59 (0.83) 0.65 (0.84) 5.30 b0.05 0.20 1.77 0.184 0.14
CDSS 4: Guilty ideas of reference 0.41 (0.79) 0.25 (0.54) 0.30 (0.60) 7.28 b0.01 0.20 2.83 0.093 0.14
CDSS 5: Pathological guilt 0.48 (0.74) 0.35 (0.65) 0.34 (0.67) 5.85 b0.05 0.18 3.51 0.061 0.19
CDSS 6: Morning depression 0.51 (0.74) 0.54 (0.81) 0.54 (0.77) 0.15 0.702 −0.04 0.05 0.829 −0.04
CDSS 7: Early awakening 0.50 (0.90) 0.39 (0.82) 0.36 (0.87) 2.29 0.130 0.12 2.42 0.120 0.16
CDSS 8: Suicide 0.18 (0.42) 0.16 (0.42) 0.15 (0.36) 0.51 0.478 0.05 0.74 0.390 0.07
CDSS 9: Observed depression 0.56 (0.75) 0.50 (0.68) 0.50 (0.68) 1.19 0.276 0.08 1.16 0.282 0.08
Notes. CDSS=Calgary Depression Scale for Schizophrenia, PANSS=Positive and Negative. Syndrome Scale, PHQ-9=Patient Health Questionnaire- 9 (depression), PSYRATS=Psychosis
Rating Scales, Delusions Subscale.– Mpre]/SDpre) for the descriptive analyses, and standardized partial
regression coefficients for the cross-lagged panel models.
3. Results
3.1. Descriptive statistics
Data from 250 patients could be included at baseline. At T1, data
from 205 participants (82.0%) was available. Six months later (T2),
approximately three-quarters of participants could be tested (n = 185
patients; 74.0%). Participants who did not take part in T1 had higher
baseline depression scores on the PHQ (p=0.03) than those who com-
pleted T1. No differences with regard to age, gender, education or de-
pressive or paranoid symptoms were detected between completers
and non-completers at T2. Table 1 summarizes the main demographic,
psychopathological and treatment-related (e.g., medication) data.
At baseline, the modal patient was male in his late 30s. Half of the
participants had 12 years ormore education (n=126, 50.5%).Most par-
ticipants were currently in psychiatric treatment, either as inpatients (n
= 133, 53.2%) or outpatients (n = 51, 20.4%). All patients met criteria
for a schizophrenia spectrum disorder. The majority of patients fulfilled
criteria of a lifetime diagnosis of depression or dysthymia according to
theM.I.N.I. – only 41.6% nevermet criteria for such diagnoses. The over-
all symptom severity of the PANSS was 60.2, which equates to rather
mild symptomatology.
Table 2 presents descriptive statistics for paranoia and depressive
symptoms over time, as well as results of t-tests for paired samples
and effect sizes based on imputed data. Paranoia significantly decreased
to a moderate degree between baseline and T1 as well as between T1
and T2. Decrease in depression was smaller than that for paranoia, but
was significant at both assessment-points (T1 and T2), especially with
regard to depressed mood, change in appetite, feelings of guilt/worth-
lessness, concentration and being slowed down/restless.
3.2. Measurement models and measurement invariance
All measurement models revealed good model fit for paranoia (CFI
= 1.00, TLI = 1.00, RMSEA = 0.00) and depression (CFI = 1.00, TLI
= 1.01, RMSEA = 0.00) at each assessment-point. Measurementinvariance was tested by comparing constrained and unconstrained
models across time. Differences for model fit were CFI = 0.000, TLI =
−0.002, RMSEA = 0.006 for paranoia and CFI = 0.000, TLI = 0.009,
RMSEA = 0.000 for depression, which is acceptable (Chen, 2007;
Cheung and Rensvold, 2002). Modification indices indicated adequate
fit for the constrained models. This ensured that assessments measured
the same constructs over time.
3.3. Correlations between depressive and paranoid symptoms over time
All model variables were significantly and positively associated with
each other at all assessment points. The only exceptions were the non-
significant correlations between both depression measures (i.e., CDSS
and PHQ) at baseline and paranoia as measured by the PANSS at T1
and T2. In general, correlations were highest for measures at the same
assessment-points.
3.4. Stability over time
In the cross-lagged panel model, regression coefficients of 0.88 (T0-
T1) and 0.86 (T1-T2) for paranoia indicate that levels of paranoia were
stable over time paralleled by significant improvement across the
three points of assessment. In comparison, stability of depression was
modest (T0-T1: β = 0.46; T1-T2: β = 0.52) (see Fig. 1). Table 3 shows
the stability coefficients using individual assessments instead of
forming latent variables. Self-reported depression (PHQ-9) demon-
strated higher stability from T0 to T1 than the expert-rated CDSS (sim-
ilar values from T1 to T2), whereas for paranoia, the PANSS was more
stable than the PSYRATS.
3.5. Cross-lagged associations between depressive and paranoid symptoms
over time
Higher levels of paranoia at baseline were significantly associated
with more depression at both T1 and at T2 (see Fig. 1). Depression at
baseline predicted paranoia at T1, but no such association occurred for
T2. Higher levels of depression at baseline were significantly associated
with less paranoia at T1. With regard to covariates, age but not gender
or years of education were significantly associated with paranoia such
Table 3
Standardized stability coefficients over time for paranoia and depression.
T0 ➔ T1 T1 ➔ T2
beta 95% CI posterior SD beta 95% CI Posterior SD
Paranoia
PANSS 0.49*** 0.40; 0.59 0.04 0.71*** 0.64; 0.78 0.04
PSYRATS 0.31*** 0.20; 0.43 0.06 0.57*** 0.44; 0.67 0.06
Depression
CDSS 0.28*** 0.18; 0.40 0.06 0.42*** 0.30; 0.52 0.06
PHQ 0.43*** 0.35; 0.52 0.04 0.46*** 0.35; 0.55 0.05
Note. ⁎⁎⁎ p b 0.001; no indicator-specific effect was estimated in these models as manifest
individual assessments were used for paranoia and depression.
CDSS= Calgary Depression Scale for Schizophrenia, PANSS= Positive and Negative Syn-
drome Scale (PANSS), PHQ-9=Patient Health Questionnaire- 9 (depression), PSYRATS=
Psychosis Rating Scales, Delusions Subscale.that older age was associated with more paranoia. None of the covari-
ates showed any significant association with depression.
The individual standardized cross-lagged coefficients are shown in
Appendix A. These parameter estimates are not as reliable as the full
model with latent factors and should be interpreted with caution. As
can be seen in Appendix A, six out of nine items from the CDSS could
predict paranoia at T1 but only two (and with lesser weight) at T2.
Items from the PHQ-9 were weak predictors overall.
4. Discussion
The present study aimed to shed further light on the temporal rela-
tionships between depressive symptoms and paranoia. A direct path
was found from paranoia to depression at both post (6 weeks) and
follow-up (6months) assessments. The reverse path was only significant
for post-assessment and was in the opposite direction than expected.
Our findings contribute to a growing literature demonstrating the
psychological problems and hardships paranoia and other positive
symptoms inflict on patients in the long run (see introduction). Clearly,
our study does not rule out a path leading fromdepressive symptoms to
paranoia as implicated in Freeman and Garety's model (Freeman, 2016;
Freeman and Garety, 2014; Garety and Freeman, 2013) but such a link-
age is perhaps more prominent in the other phases of the disorder
(e.g., clinical high risk state, before relapse).
The present study has a number of strengths but also weaknesses. A
strength is seen in the large sample of patients with a diagnosed schizo-
phrenia spectrum disorder and the good retention rate. Moreover, the
instruments are well established for the measurement of both paranoia
and depression; test-retest reliability was satisfactory to good, particu-
larly for paranoia. Importantly, we used a self-report as well as a
clinician-rated instrument to assess depression as both sources obtain
unique information (Uher et al., 2012). A serious limitation is that we
have no data on longer intervals; results from midterm and long-term
follow-upsmay vary greatly (Moritz et al., 2017a, 2017b). Thus, we can-
not say whether the relationship from paranoia towards depression is
strengthened over time or even reverts. A problem with this and most
other studies in the field is that no gold standard exists for themeasure-
ment of depression in schizophrenia. Findings tentatively suggest that
results are not congruent for self-report and expert rating scales (Uher
et al., 2012). Of more concern, a lot of different aspects (e.g., worry,Fig. 1. Cross-lagged panel model of the relationships between paranoia and depression.Model fi
=0.04; 0.07)Notes. Only significant coefficients are displayed; rectangles present observedman
** p b 0.01, *** p b 0.001.rumination, explicit or implicit self-esteem, depression, etc.) captured
by very different scales are subsumed under the umbrella term “nega-
tive affect”. Studies in the field are therefore perhaps more inconsistent
than it appears from abstracts. Moreover, although cross-laggedmodels
are now regarded as one of the most appropriate statistical techniques
to study relationships between model variables prospectively, they
have also been subject to criticism (Hamaker et al., 2015). Finally, our
sample was mainly chronic; few patients (15.6%) were experiencing
their first episode, which may have obscured stronger causal relation-
ships between depression and paranoia as highlighted in the model by
Freeman and Garety (see below).
Whatever the relationship between depression and paranoia across
different stages of the schizophrenia spectrum disorder (e.g., paranoia
predicting depression in remission, depression predicting paranoia in
the clinical high risk state), we need to redefine the role of depression
for the treatment of patients. So far, positive and negative symptoms
of schizophrenia have been the primary treatment targets and typical
outcomes of most contemporary research, which may partly be due to
the fact that these symptoms are (allegedly) easier to treat with anti-
psychotic medication. In addition, positive and negative symptoms
have represented hallmark symptoms of schizophrenia for decades,
whereas depression has received attention only until recently. How-
ever, prevalence of depression in this population is high (Buckley
et al., 2009) and patients themselves attribute a high priority to thet indices: χ2(61)= 106.40, p b 0.001; CFI= 0.97; TLI= 0.95; RMSEA= 0.06, p=0.391 (CIs
ifest variables, ovals unobserved latent variables; values are standardizedpath coefficients.
treatment of depressive symptoms (Byrne et al., 2010; Kuhnigk et al.,
2012; Moritz et al., 2017a, 2017b). Depression is also related to suicidal
ideation, self-stigma and treatment fatalism.
Our results corroborate prior studies showing that patientswith para-
noiamayneed special care in termsof bothpsychosis anddepressionpro-
phylaxis after discharge. This holds true especially for those whose social
network has been strained by psychosis (e.g., in case they insulted,
attacked or neglected other people, especially significant others during
psychosis), which may cause despair and shame (Sandhu et al., 2013).
Losing one's job or participating only in low-paid work in sheltered em-
ployment may contribute to feelings of low social rank (Birchwood
et al., 2005), which heightens the risk for depression.
Like in our forerunner study with nonclinical participants, depres-
sive and paranoid symptoms were stable over time. At baseline, para-
noia was highly correlated with depression confirming that affective
and psychotic symptoms are more closely associated than assumed
from a “Kraepelian” viewpoint.
Although our findings do not support a causal association between
high depressive symptoms and subsequent paranoia (at least at the clin-
ical stages tested in our sample), these associations are worth further in-
vestigation; affective symptoms are associated with suffering and thus
remain an important clinical target. The unexpected negative association
between baseline depression and post paranoia needs to be replicated
and should be regarded an outlier until then. Most studies found either
null or positive associations and we would like to reiterate our former
call not only to examine the statistical associations between psychotic
and affective symptoms, but to truly understand the dynamics behind
them(Westermann et al., 2015). Such linkagesmaybe quite idiosyncratic
and thus may only hold for specific subgroups. To illustrate, poor drive,
avoidance andwithdrawal limit corrective experiences and positive feed-
back fromothers. As Zimbardo (1999)has argued, this likely fosters a sen-
timent of abandonment, which may result in paranoia. For a subgroup of
patients, poor self-esteemmay trigger the wish for personal importance,
which could act as a maintenance factor for delusional ideas that contain
grandiose elements (Moritz et al., 2015a, 2015b; Sundag et al., 2015).
Sleep problems and cognitive problems due to depressive thoughts can
interfere with cognition and prompt “weird ideas” (Moritz et al., 2017a,
2017b). Put differently, we should try to track the domino pieces that
may go from depression to paranoia.
It deserves to be tested whether it is the social and functional conse-
quences of negative affect that contribute to paranoia and not the depres-
sive symptoms as such. As argued above, this may also apply for the
opposite relationship: paranoia likely interferes with the social and work
environment and any such challenges may prompt depressive symptoms
via feelings of shame, entrapment and a reduction in perceived social rank.
Taken together, we agreewith Freeman et al. (2014) that improving emo-
tional well-being including depression is important in its own right –
whether or not it is related to future positive symptoms such as paranoia.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.schres.2019.06.022.
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